The first EGFR inhibitor, gefitinib, was initially approved for the treatment of NSCLC regardless of mutation status based on phase II data, which did not translate to improved outcomes in large phase III trials and led to the withdrawal of gefitinib from the US market unless patients were receiving the drug and benefiting [54]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.